An in vivo multiplexed small-molecule screening platform

Nature Methods

Volumn 13, Issue 10, 2016, Pages 883-889

  Grüner, Barbara M ^a   Schulze, Christopher J ^a   Yang, Dian ^a   Ogasawara, Daisuke ^b   Dix, Melissa M ^b   Rogers, Zoë N ^a   Chuang, Chen Hua ^a   McFarland, Christopher D ^c   Chiou, Shin Heng ^a   Brown, J Mark ^d   Cravatt, Benjamin F ^b   Bogyo, Matthew ^a,e   Winslow, Monte M ^a,e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROLASE; LIPASE ABHD6; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; ABHD6 PROTEIN, HUMAN; ABHD6 PROTEIN, MOUSE; ACYLGLYCEROL LIPASE; MOLECULAR LIBRARY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA BARCODING; EMBRYO; GENE TARGETING; GENETIC SCREENING; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR LIBRARY; MOUSE; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; TUMOR SEEDING; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; GENE SILENCING; GENETICS; HIGH THROUGHPUT SCREENING; LIVER TUMOR; METABOLISM; MOLECULAR IMAGING; PANCREAS TUMOR; PATHOLOGY; PHARMACOLOGY; PRECLINICAL STUDY; PROCEDURES; SCID MOUSE; SECONDARY; TUMOR CELL LINE;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GENE KNOCKDOWN TECHNIQUES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIVER NEOPLASMS; MICE; MICE, SCID; MOLECULAR IMAGING; MONOACYLGLYCEROL LIPASES; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; SMALL MOLECULE LIBRARIES;

EID: 84987653503     PISSN: 15487091     EISSN: 15487105     Source Type: Journal    
DOI: 10.1038/nmeth.3992     Document Type: Article

References (49)

1. Schirle, M. & Jenkins, J. L. Identifying compound efficacy targets in phenotypic drug discovery. Drug Discov. Today 21, 82-89 (2016).
2. Bassilana, F. et al. Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39. Nat. Chem. Biol. 10, 343-349 (2014).
3. Chen, X., Barclay, J. W., Burgoyne, R. D. & Morgan, A. Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases. Chem. Cent. J. 9, 65 (2015).
4. Rennekamp, A. J. & Peterson, R. T. 15 years of zebrafish chemical screening. Curr. Opin. Chem. Biol. 24, 58-70 (2015).
5. Hannan, S. B., Dräger, N. M., Rasse, T. M., Voigt, A. & Jahn, T. R. Cellular and molecular modifier pathways in tauopathies: The big picture from screening invertebrate models. J. Neurochem. 137, 12-25 (2016).
6. Jonas, O. et al. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci. Transl. Med. 7, 284ra57 (2015).
7. Klinghoffer, R. A. et al. A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Sci. Transl. Med. 7, 284ra58 (2015).
8. Wagenblast, E. et al. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature 520, 358-362 (2015).
9. Bhang, H. E. et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21, 440-448 (2015).
10. Lu, R., Neff, N. F., Quake, S. R. & Weissman, I. L. Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding. Nat. Biotechnol. 29, 928-933 (2011).
11. Naik, S. H. et al. Diverse and heritable lineage imprinting of early haematopoietic progenitors. Nature 496, 229-232 (2013).
12. Fan, H. C., Fu, G. K. & Fodor, S. P. Expression profiling. Combinatorial labeling of single cells for gene expression cytometry. Science 347, 1258367 (2015).
13. Yu, C. et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat. Biotechnol. 34, 419-423 (2016).
14. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015).
15. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
16. Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168-1178 (2015).
17. Knudsen, E. S., O'Reilly, E. M., Brody, J. R. & Witkiewicz, A. K. Genetic diversity of pancreatic ductal adenocarcinoma and opportunities for precision medicine. Gastroenterology 150, 48-63 (2015).
18. Yachida, S. & Iacobuzio-Donahue, C. A. The pathology and genetics of metastatic pancreatic cancer. Arch. Pathol. Lab. Med. 133, 413-422 (2009).
19. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
20. Whittle, M. C. et al. RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma. Cell 161, 1345-1360 (2015).
21. Guan, X. Cancer metastases: challenges and opportunities. Acta Pharm. Sin. B 5, 402-418 (2015).
22. Zhang, Y., Zhang, W. & Qin, L. Mesenchymal-mode migration assay and antimetastatic drug screening with high-throughput microfluidic channel networks. Angew. Chem. Int. Ed. Engl. 53, 2344-2348 (2014).
23. Colas, P. High-throughput screening assays to discover small-molecule inhibitors of protein interactions. Curr. Drug Discov. Technol. 5, 190-199 (2008).
24. Budczies, J. et al. The landscape of metastatic progression patterns across major human cancers. Oncotarget 6, 570-583 (2015).
25. Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483 (2005).
26. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
27. Arastu-Kapur, S. et al. Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum. Nat. Chem. Biol. 4, 203-213 (2008).
28. Hall, C. I. et al. Chemical genetic screen identifies Toxoplasma DJ-1 as a regulator of parasite secretion, attachment, and invasion. Proc. Natl. Acad. Sci. USA 108, 10568-10573 (2011).
29. Child, M. A. et al. Small-molecule inhibition of a depalmitoylase enhances Toxoplasma host-cell invasion. Nat. Chem. Biol. 9, 651-656 (2013).
30. Sipos, B. et al. A comprehensive characterization of pancreatic ductal carcinoma cell lines: Towards the establishment of an in vitro research platform. Virchows Arch. 442, 444-452 (2003).
31. Jessani, N. et al. A streamlined platform for high-content functional proteomics of primary human specimens. Nat. Methods 2, 691-697 (2005).
32. Boersema, P. J., Raijmakers, R., Lemeer, S., Mohammed, S. & Heck, A. J. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat. Protoc. 4, 484-494 (2009).
33. Hsu, K. L. et al. Discovery and optimization of piperidyl-1, 2, 3-triazole ureas as potent, selective, and in vivo-active inhibitors of /-hydrolase domain containing 6 (ABHD6). J. Med. Chem. 56, 8270-8279 (2013).
34. Marrs, W. R. et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat. Neurosci. 13, 951-957 (2010).
35. Thomas, G. et al. The serine hydrolase ABHD6 is a critical regulator of the metabolic syndrome. Cell Rep. 5, 508-520 (2013).
36. Alhouayek, M., Masquelier, J., Cani, P. D., Lambert, D. M. & Muccioli, G. G. Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6. Proc. Natl. Acad. Sci. USA 110, 17558-17563 (2013).
37. Zhao, S. et al. /-hydrolase domain-6-accessible monoacylglycerol controls glucose-stimulated insulin secretion. Cell Metab. 19, 993-1007 (2014).
38. Hsu, K. L. et al. DAGL inhibition perturbs a lipid network involved in macrophage inflammatory responses. Nat. Chem. Biol. 8, 999-1007 (2012).
39. Thomas, G., Brown, A. L. & Brown, J. M. In vivo metabolite profiling as a means to identify uncharacterized lipase function: recent success stories within the alpha beta hydrolase domain (ABHD) enzyme family. Biochim. Biophys. Acta 1841, 1097-1101 (2014).
40. Pribasnig, M. A. et al. / hydrolase domain-containing 6 (ABHD6) degrades the late endosomal/lysosomal lipid bis(monoacylglycero)phosphate. J. Biol. Chem. 290, 29869-29881 (2015).
41. Nomura, D. K. et al. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem. Biol. 18, 846-856 (2011).
42. Nomura, D. K. et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140, 49-61 (2010).
43. Max, D., Hesse, M., Volkmer, I. & Staege, M. S. High expression of the evolutionarily conserved alpha/beta hydrolase domain containing 6 (ABHD6) in Ewing tumors. Cancer Sci. 100, 2383-2389 (2009).
44. Steeg, P. S. Targeting metastasis. Nat. Rev. Cancer 16, 201-218 (2016).
45. Li, C. M. et al. Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes Dev. 27, 1557-1567 (2013).
46. Inloes, J. M. et al. The hereditary spastic paraplegia-related enzyme DDHD2 is a principal brain triglyceride lipase. Proc. Natl. Acad. Sci. USA 111, 14924-14929 (2014).
47. Washburn, M. P., Wolters, D. & Yates, J. R. III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19, 242-247 (2001).
48. Weerapana, E. et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468, 790-795 (2010).
49. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).